guest ::
| Home > Publications database > Circulating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses. > print |
| Home > Publications database > Circulating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses. > print |
| 001 | 293318 | ||
| 005 | 20250820121129.0 | ||
| 024 | 7 | _ | |a pmid:39278107 |2 pmid |
| 024 | 7 | _ | |a DOI:10.1016/j.ebiom.2024.105341 |2 doi |
| 024 | 7 | _ | |a DOI:10.1016/j.ebiom.2024.105341 |2 doi |
| 024 | 7 | _ | |a altmetric:167749718 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01871 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wang, Sabrina E |b 0 |
| 245 | _ | _ | |a Circulating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726571726_12012 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Inflammation and immune dysregulation are hypothesized contributors to endometrial carcinogenesis; however, the precise underlying mechanisms remain unclear.We measured pre-diagnostically 152 plasma protein biomarkers in 624 endometrial cancer case-control pairs nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Odds ratios (ORs) were estimated using conditional logistic regression, accounting for confounding and multiple comparisons. Proteins considered as associated with endometrial cancer risk were further tested in a two-sample Mendelian randomization (MR) analysis using summary data from the UK Biobank (n = 52,363) and the Endometrial Cancer Association Consortium (12,270 cases and 46,126 controls).In the EPIC nested case-control study, IL-6 [OR per NPX (doubling of concentration) = 1.28 (95% confidence interval (CI) 1.03-1.57)], HGF [1.48 (1.06-2.07)], PIK3AP1 [1.22 (1.00-1.50)] and CLEC4G [1.52 (1.00-2.32)] were positively associated; HSD11B1 [0.67 (0.49-0.91)], SCF [0.68 (0.49-0.94)], and CCL25 [0.80 (0.65-0.99)] were inversely associated with endometrial cancer risk; all estimates had multiple comparisons adjusted P-value > 0.05. In complementary MR analysis, IL-6 [OR per inverse-rank normalized NPX = 1.19 (95% CI 1.04-1.36)] and HSD11B1 [0.91 (0.84-0.99)] were associated with endometrial cancer risk.Altered IL-6 signalling and reduced glucocorticoid activity via HSD11B1 might play important roles in endometrial carcinogenesis.Funding for IIG_FULL_2021_008 was obtained from Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme; Funding for INCA_15849 was obtained from Institut National du Cancer (INCa). |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Endometrial cancer |2 Other |
| 650 | _ | 7 | |a HSD11B1 |2 Other |
| 650 | _ | 7 | |a Interleukin-6 |2 Other |
| 650 | _ | 7 | |a Mendelian randomisation |2 Other |
| 650 | _ | 7 | |a Proteomics |2 Other |
| 700 | 1 | _ | |a Viallon, Vivian |b 1 |
| 700 | 1 | _ | |a Lee, Matthew |b 2 |
| 700 | 1 | _ | |a Dimou, Niki |b 3 |
| 700 | 1 | _ | |a Hamilton, Fergus |b 4 |
| 700 | 1 | _ | |a Biessy, Carine |b 5 |
| 700 | 1 | _ | |a O'Mara, Tracy |b 6 |
| 700 | 1 | _ | |a Kyrgiou, Maria |b 7 |
| 700 | 1 | _ | |a Crosbie, Emma J |b 8 |
| 700 | 1 | _ | |a Truong, Therese |b 9 |
| 700 | 1 | _ | |a Severi, Gianluca |b 10 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 11 |u dkfz |
| 700 | 1 | _ | |a Fortner, Renée Turzanski |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 12 |u dkfz |
| 700 | 1 | _ | |a Schulze, Matthias B |b 13 |
| 700 | 1 | _ | |a Bendinelli, Benedetta |b 14 |
| 700 | 1 | _ | |a Sabina, Sieri |b 15 |
| 700 | 1 | _ | |a Tumino, Rosario |b 16 |
| 700 | 1 | _ | |a Sacerdote, Carlotta |b 17 |
| 700 | 1 | _ | |a Panico, Salvatore |b 18 |
| 700 | 1 | _ | |a Crous-Bou, Marta |b 19 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |b 20 |
| 700 | 1 | _ | |a Aizpurua, Amaia |b 21 |
| 700 | 1 | _ | |a Palacios, Daniel Rodriguez |b 22 |
| 700 | 1 | _ | |a Guevara, Marcela |b 23 |
| 700 | 1 | _ | |a Travis, Ruth C |b 24 |
| 700 | 1 | _ | |a Tsilidis, Konstantinos K |b 25 |
| 700 | 1 | _ | |a Heath, Alicia |b 26 |
| 700 | 1 | _ | |a Yarmolinsky, James |b 27 |
| 700 | 1 | _ | |a Rinaldi, Sabina |b 28 |
| 700 | 1 | _ | |a Gunter, Marc J |b 29 |
| 700 | 1 | _ | |a Dossus, Laure |b 30 |
| 773 | _ | _ | |a DOI:10.1016/j.ebiom.2024.105341 |g Vol. 108 |0 PERI:(DE-600)2799017-5 |p 105341 |t EBioMedicine |v 108 |y 2024 |x 2352-3964 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293318/files/1-s2.0-S2352396424003773-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293318/files/1-s2.0-S2352396424003773-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:293318 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EBIOMEDICINE : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:51:17Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-26 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b EBIOMEDICINE : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-26 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-26 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|